The latest 2017 European Leukemia Net (ENL) guidelines for AML recommends molecular profiling for mutations in NPM1, CEBPA, FLT3-ITD, TP53, RUNX1, ASXL1, and BCR-ABL1. Therefore, the complete cytogenetic and molecular work-up is essential at the time of initial AML evaluation. This evidence concerns the gene TP53 and acute myeloid leukemia.